Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors
详细信息 查看全文
- 作者：Evgeny Klyuchnikov1 ; Ulrike Bacher2 ; Nicolaus M. Krö ; ger1 ; Parameswaran N. Hari3 ; Kwang Woo Ahn3 ; 4 ; Jeanette Carreras3 ; Veronika Bachanova5 ; Asad Bashey6 ; Jonathon B. Cohen7 ; Anita D'Souza3 ; Cé ; sar O. Freytes8 ; Robert Peter Gale9 ; Siddhartha Ganguly10 ; Mark S. Hertzberg11 ; Leona A. Holmberg12 ; Mohamed A. Kharfan-Dabaja13 ; Andreas Klein14 ; Grace H. Ku15 ; Ginna G. Laport16 ; Hillard M. Lazarus17 ; Alan M. Miller18 ; Alberto Mussetti19 ; 20 ; Richard F. Olsson21 ; 22 ; Shimon Slavin23 ; Saad Z. Usmani24 ; Ravi Vij25 ; William A. Wood26 ; David G. Maloney12 ; Anna M. Sureda27 ; 28 ; Sonali M. Smith29 ; Mehdi Hamadani3 ; mhamadani@mcw.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：Grade 1 and 2 follicular lymphoma ; Reduced-intensity allogeneic hematopoietic cell transplantation ; Autologous hematopoietic cell transplantation ; Long-time survival
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2015
- 出版时间：December 2015
- 年：2015
- 卷：21
- 期：12
- 页码：2091-2099
- 全文大小：395 K
文摘
- titem" id="list_olist0010">
We conducted the largest study comparing autologous hematopoietic cell transplantation with allogeneic hematopoietic cell transplantation in grades 1 and 2 follicular lymphoma in rituximab era.
In follicular lymphoma patients surviving 2 years after hematopoietic cell transplantation, allografting provided an overall survival benefit.
Rituximab resistance does not predict hematopoietic cell transplantation outcomes.
Overall survival was better in those with hematopoietic cell transplantation performed from 2008 onward.
Second hematological malignancies develop only after a autologous hematopoietic cell transplantation.